/A Pilot Study of the Pharmacodynamic Impact of SSRI Drug Selection and Beta-1 Receptor Genotype (ADRB1) on Cardiac Vital Signs in Depressed Patients: A Novel Pharmacogenetic Approach

A Pilot Study of the Pharmacodynamic Impact of SSRI Drug Selection and Beta-1 Receptor Genotype (ADRB1) on Cardiac Vital Signs in Depressed Patients: A Novel Pharmacogenetic Approach

$30.00

A Pilot Study of the Pharmacodynamic Impact of SSRI Drug Selection and Beta-1 Receptor Genotype (ADRB1on Cardiac Vital Signs in Depressed Patients: A Novel Pharmacogenetic Approach

By Kelan L.H. Thomas, Vicki L. Ellingrod, Jeffrey R. Bishop, Michael J. Keiser

Want a discount? Become a member by purchasing Psychopharmacology Bulletin Subscription - Individual!

Description

Original Research

A Pilot Study of the Pharmacodynamic Impact of SSRI Drug Selection and Beta-1 Receptor Genotype (ADRB1on Cardiac Vital Signs in Depressed Patients: A Novel Pharmacogenetic Approach

By Kelan L.H. Thomas, Vicki L. Ellingrod, Jeffrey R. Bishop, Michael J. Keiser

PB-43-1-2010_ELLINGROD